These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 27117315)

  • 1. Effectiveness of the Polish program for the treatment of severe allergic asthma with omalizumab: a single-center experience.
    Kupryś-Lipińska I; Majak P; Molinska J; Kuna P
    BMC Pulm Med; 2016 Apr; 16(1):61. PubMed ID: 27117315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of asthma control and quality of life in severe allergic asthmatics under treatment with anti-IgE, omalizumab].
    Pacheco-Galván A; Hinojosa-Macías M; Hurtado-Barbudo B; González-Cervera J; Sueiro-Bendito A
    Med Clin (Barc); 2009 Oct; 133(12):460-3. PubMed ID: 19775710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients.
    Siergiejko Z; Świebocka E; Smith N; Peckitt C; Leo J; Peachey G; Maykut R
    Curr Med Res Opin; 2011 Nov; 27(11):2223-8. PubMed ID: 21933100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omalizumab in patients with severe asthma: the XCLUSIVE study.
    Schumann C; Kropf C; Wibmer T; Rüdiger S; Stoiber KM; Thielen A; Rottbauer W; Kroegel C
    Clin Respir J; 2012 Oct; 6(4):215-27. PubMed ID: 21740532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
    Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
    J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry.
    Gibson PG; Reddel H; McDonald VM; Marks G; Jenkins C; Gillman A; Upham J; Sutherland M; Rimmer J; Thien F; Katsoulotos GP; Cook M; Yang I; Katelaris C; Bowler S; Langton D; Robinson P; Wright C; Yozghatlian V; Burgess S; Sivakumaran P; Jaffe A; Bowden J; Wark PA; Yan KY; Kritikos V; Peters M; Hew M; Aminazad A; Bint M; Guo M
    Intern Med J; 2016 Sep; 46(9):1054-62. PubMed ID: 27350385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma.
    Chapman KR; Albers FC; Chipps B; Muñoz X; Devouassoux G; Bergna M; Galkin D; Azmi J; Mouneimne D; Price RG; Liu MC
    Allergy; 2019 Sep; 74(9):1716-1726. PubMed ID: 31049972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study.
    Bhutani M; Yang WH; Hébert J; de Takacsy F; Stril JL
    PLoS One; 2017; 12(8):e0183869. PubMed ID: 28859150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany.
    Korn S; Thielen A; Seyfried S; Taube C; Kornmann O; Buhl R
    Respir Med; 2009 Nov; 103(11):1725-31. PubMed ID: 19515548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and economic impact of a one-year treatment with omalizumab in patients with severe allergic asthma within a drug programme in Poland.
    Jahnz-Różyk K; Lis J; Warchoł M; Kucharczyk A
    BMC Pulm Med; 2018 Mar; 18(1):48. PubMed ID: 29548318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A step-down protocol for omalizumab treatment in oral corticosteroid-dependent allergic asthma patients.
    Domingo C; Pomares X; Navarro A; Amengual MJ; Montón C; Sogo A; Mirapeix RM
    Br J Clin Pharmacol; 2018 Feb; 84(2):339-348. PubMed ID: 29044640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study.
    Brusselle G; Michils A; Louis R; Dupont L; Van de Maele B; Delobbe A; Pilette C; Lee CS; Gurdain S; Vancayzeele S; Lecomte P; Hermans C; MacDonald K; Song M; Abraham I
    Respir Med; 2009 Nov; 103(11):1633-42. PubMed ID: 19619998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy.
    Odajima H; Ebisawa M; Nagakura T; Fujisawa T; Akasawa A; Ito K; Doi S; Yamaguchi K; Katsunuma T; Kurihara K; Kondo N; Sugai K; Nambu M; Hoshioka A; Yoshihara S; Sato N; Seko N; Nishima S
    Allergol Int; 2015 Oct; 64(4):364-70. PubMed ID: 26433533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteria.
    Hew M; Gillman A; Sutherland M; Wark P; Bowden J; Guo M; Reddel HK; Jenkins C; Marks GB; Thien F; Rimmer J; Katsoulotos GP; Cook M; Yang I; Katelaris C; Bowler S; Langton D; Wright C; Bint M; Yozghatlian V; Burgess S; Sivakumaran P; Yan KY; Kritikos V; Peters M; Baraket M; Aminazad A; Robinson P; Jaffe A; Powell H; Upham JW; McDonald VM; Gibson PG
    Clin Exp Allergy; 2016 Nov; 46(11):1407-1415. PubMed ID: 27377155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of long-term omalizumab treatment in patients with severe allergic asthma long-term omalizumab treatment in severe asthma.
    Özgür ES; Özge C; Ïlvan A; Naycı SA
    J Asthma; 2013 Aug; 50(6):687-94. PubMed ID: 23557459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
    Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
    Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of omalizumab in severe, persistent IgE-mediated asthma in pediatric and adult patients: a real-world observational study in Egyptian population.
    Tarraf HN; Masoud HH; Zidan M; Wahba B
    J Asthma; 2020 Feb; 57(2):160-166. PubMed ID: 30592242
    [No Abstract]   [Full Text] [Related]  

  • 18. The Long-Term Effectiveness and Safety of Omalizumab on Patient- and Physician-Reported Asthma Control: A Three-Year, Real-Life Observational Study.
    Schreiber J; Schwab Sauerbeck I; Mailänder C
    Adv Ther; 2020 Jan; 37(1):353-363. PubMed ID: 31741282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The real-life clinical effects of 52 weeks of omalizumab therapy for severe persistent allergic asthma.
    Gouder C; West LM; Montefort S
    Int J Clin Pharm; 2015 Feb; 37(1):36-43. PubMed ID: 25394832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of omalizumab in children and adolescents with uncontrolled allergic asthma: a case series from Poland.
    Sztafińska A; Gwardys M; Podlecka D; Mospinek E; Stelmach I
    Postepy Dermatol Alergol; 2021 Jun; 38(3):427-432. PubMed ID: 34377123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.